Evidence map›Paper›PMID 36438599›Full record

ArticleBiochemistry and biophysics reports2022

Prognostic pyroptosis-related lncRNA signature predicts the efficacy of immunotherapy in hepatocellular carcinoma.

Zina Cheng, Juechen Han, Fa Jiang, Weiyi Chen, Xiaolu Ma

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biochemistry and biophysics reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Zina ChengCollege of Biomedical Engineering, Taiyuan University of Technology, Taiyuan, 030024, China.
Juechen HanCollege of Biomedical Engineering, Taiyuan University of Technology, Taiyuan, 030024, China.
Fa JiangCollege of Biomedical Engineering, Taiyuan University of Technology, Taiyuan, 030024, China.
Weiyi ChenCollege of Biomedical Engineering, Taiyuan University of Technology, Taiyuan, 030024, China.
Xiaolu MaCollege of Biomedical Engineering, Taiyuan University of Technology, Taiyuan, 030024, China.
Taiyuan University of Technology · CNUniversity of Chinese Academy of Sciences · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hepatocellular carcinoma (HCC), a common malignant tumor of the liver, remains high incidence and poor prognosis. Although pyroptosis as well as lncRNA have been believed to play important roles in the tumorigenesis, diagnosis and prognosis, the role of pyroptosis-related lncRNAs (PRlncRs) in HCC remains obscure. Here, we identified 73 significantly differentially expressed and overall survival (OS) related pyroptosis-related lncRNAs (PRlncRs) in noncancerous and HCC samples. Based on LASSO regression and Cox regression analyses, we set up a novel prognostic model including six PRlncRs (MKLN1-AS, AC139491.2, AC145207.5, AC099850.3, AL590705.3 and AL049840.5), which showed good correlation with the OS of HCC patients. Considering that the risk score was negatively related to clinicopathologic features including T stage (T1-2 and T3-4), clinical stage (stage I-II and stage III-IV) and histological grade (G1, G2, G3 and G4), we further constructed a predictive nomogram containing the risk score and other clinicopathological features to predict the OS rates for HCC patients. In addition, the proposed signature was closely related to immune infiltration and offered improved clinical utility for immune checkpoint inhibitors (ICIs) strategies and chemotherapeutic drug selection in HCC. In conclusion, we established a considerable accurate risk signature consisting of 6 PRlncRs in HCC, which could predict the prognosis and efficacy of immunotherapy for HCC patients.

Indexed as

Hepatocellular carcinomaImmunotherapyLong non-coding RNAPyroptosis

Identifiers

PMID36438599
PMCPMC9684700
OpenAlexW4309768140

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.